

Electronic Filing System (EFS) Data **Electronic Patent Application Submission** RECEIVED MAR 0 3 2003 TECH CENTER 1600/2900 **USPTO Use Only**

EFS ID:

23741

Application ID:

09242977

Title of Invention:

Method for Recombinant Adeno-Associated Virus-Directed Gene

Therapy

First Named Inventor:

James Wilson

Domestic/Foreign Application:

Domestic Application

Filing Date:

1999-02-26

Effective Receipt Date:

2003-02-26

Submission Type:

Information Disclosure Statement

Filing Type:

null

Confirmation Number:

1765

Attorney Docket Number:

GNV19BUSA

cn=Cathy A. Kodroff, ou=Registered Attorneys, ou=Patent and

Digital Certificate Holder:

Trademark Office, ou=Department of Commerce, o=U.S.

Government, c=US

Certificate Message Digest:

D5Fw8KoPNyZxQB7NCBFz3Q==

Total Fees Authorized:

\$0.0

Payment Category:

DA - Deposit Account

Deposit Account Number:

83040

Deposit Account Name:

Cathy A Kodroff



FEE TRANSMITTAL

Electronic Version 1.1.0 Stylesheet Version: 1.0

Patent fees are subject to annual revisions on or about October 1st of each year.

Large Entity

TOTAL FEES AUTHORIZED: \$ 0

The commissioner is hereby authorized to charge indicated processing and/or publication fees and credit any overpayments to:

Deposit Account Number:

08-3040

Deposit Account Name:

HOWSON&HOWSON

Charge Any Additional Fee Required Under 37 C.F.R. Sections 1.16 and 1.17.

SUBMITTED BY

Authorized Name:

Cathy A Kodroff

Electronic Signature Mark:

/cathyakodroff/

Date Signed:

20030226



TRANSMITTAL FORM

Electronic Version 1.0.3

Stylesheet Version: 1.0

Submission Type: Information

Disclosure Statement

Application

Number:

09/242,977

Attorney Docket

Number:

GNV19BUSA

Method for Recombinant Adeno-Associated Virus-Directed Gene Therapy

First Named Inventor: James M Wilson

SUBMITTED BY

Name:

Cathy A Kodroff

Registration Number:

33,980

Electronic Signature Mark:

cathyakodroff

Date Signed: 20030226

RECEIVED

MAR 0 3 2003

TECH CENTER 1600/2900

I certify that the use of this system is for OFFICIAL correspondence between patent applicants or their representatives and the USPTO. Fraudulent or other use besides the filing of official correspondence by authorized parties is strictly prohibited, and subject to a fine and/or imprisonment under applicable law.

I, the undersigned, certify that I have viewed a display of document(s) being electronically submitted to the United States Patent and Trademark Office, using either the USPTO provided style sheet or software, and that this is the document(s) I intend for initiation or further prosecution of a patent application noted in the submission. This document(s) will become part of the official electronic record at the USPTO.

Attached Files:

us-information-disclosure-statement

Podsakoffids.xml

fee-transmittal

Podsakofffee.xml

Comments:

APP_ID=09242977 Page 2 of 2

Electronic Information Disclosure Statement

Method for Recombinant Adeno-Associated Virus-Directed Gene Therapy

Application:

FEB 2 6 2003

Confirmation:

1765

Applicant(s):

James Wilson

Docket Number:

GNV19BUSA

Group Art Unit:

1632

Examiner:

R. Shukla

search string:

(5962313).pn.

US Patent Documents

Note: Applicant is not required to submit a paper copy of cited US Patent Documents

init	Citation No.	Patent Number	Date	Bar Code	Patentee	Class	Subclass
	P01	5962313	1999-10-05		Podsakoff et al	435	320.1

RPS 3

3/20/03

Remarks

(Remarks are not for responding to an office action.)

Kindly consider this document in the course of examining this application.

09/242977 IDS fled 2/26/03

Signature

Examiner Name	Date	
RUS	3/20/03	